A61K 31/713
Double-stranded nucleic acids or oligonucleotides
A61K31/713 (Double-stranded nucleic acids or oligonucleotides) appears on 3,564 US grants and 7,227 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,564
- Published applications
- 7,227
- Assignees
- 2,137
- Inventors
- 11,074
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 5 |
| 2003 | 2 | 16 |
| 2004 | 2 | 19 |
| 2005 | 2 | 25 |
| 2006 | 4 | 40 |
| 2007 | 5 | 47 |
| 2008 | 3 | 69 |
| 2009 | 26 | 98 |
| 2010 | 41 | 161 |
| 2011 | 47 | 195 |
| 2012 | 100 | 226 |
| 2013 | 137 | 373 |
| 2014 | 168 | 451 |
| 2015 | 276 | 489 |
| 2016 | 285 | 540 |
| 2017 | 330 | 427 |
| 2018 | 296 | 497 |
| 2019 | 301 | 440 |
| 2020 | 274 | 445 |
| 2021 | 252 | 460 |
| 2022 | 271 | 553 |
| 2023 | 206 | 433 |
| 2024 | 205 | 470 |
| 2025 | 183 | 430 |
| 2026 | 133 | 318 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Long-acting low-toxicity novel cationic lipid compounds and composition thereof29 Sep 2026US 12,746,208 B2Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Stealth lipid nanoparticle compositions for cell targeting29 Sep 2026US 12,746,209 B2Generation Bio Co.
- Methods for X chromosome reactivation29 Sep 2026US 12,746,254 B2The Regents of the University of California
- Oligonucleotide for inducing N-exon skipping during rest mRNA precursor processing22 Sep 2026US 12,740,997 B2Osaka University
- An intelligent charge switchable polymer-lipid hybrid system for in vivo delivery of molecules including rnas1 Oct 2026US 2026/0294830 A1Qurcan Therapeutics Inc.
- Treatment of hemophilia with fitusiran1 Oct 2026US 2026/0294956 A1Genzyme Corporation
- Therapeutic circular dna forms1 Oct 2026US 2026/0294957 A1Flagship Pioneering Innovations Vii, LLC
- Modified delivery vector and use thereof1 Oct 2026US 2026/0295082 A1Shenzhen Shenxin Biotechnology Co., Ltd.
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Cationic lipids and methods for the delivery of therapeutic agents380US 8,569,256 B2Protiva Biotherapeutics, Inc. · 2013
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Lipid formulations for nucleic acid delivery334US 8,058,069 B2Protiva Biotherapeutics, Inc. · 2011
- Carbohydrate conjugates as delivery agents for oligonucleotides273US 8,106,022 B2Alnylam Pharmaceuticals, Inc. · 2012